To determine whether clinical responses matched the pattern of sensitivity to EGFR TKIs that we observed in vitro, we assembled data from 19 NSCLC patients with diverse EGFR exon 20 insertion mutations who were treated with reversible EGFR TKIs (Fig. 2A, 2B, Sup. Table 3)....almost all 19 NSCLC patients from our centers displayed progressive disease (PD) in the course of treatment with gefitinib or erlotinib (Fig. 2B, Sup. Table 3, and Sup. Fig. 5).